These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 8374522)
21. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322 [TBL] [Abstract][Full Text] [Related]
22. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. Preisler HD; Rustum Y; Priore RL Eur J Cancer Clin Oncol; 1985 Jan; 21(1):23-30. PubMed ID: 4038655 [TBL] [Abstract][Full Text] [Related]
23. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ; Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572 [TBL] [Abstract][Full Text] [Related]
25. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Plunkett W; Nowak B; Keating MJ Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973 [TBL] [Abstract][Full Text] [Related]
26. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042 [TBL] [Abstract][Full Text] [Related]
27. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Tsimberidou AM; O'Brien SM; Cortes JE; Faderl S; Andreeff M; Kantarjian HM; Keating MJ; Giles FJ Leuk Lymphoma; 2002 Apr; 43(4):767-72. PubMed ID: 12153163 [TBL] [Abstract][Full Text] [Related]
28. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662 [TBL] [Abstract][Full Text] [Related]
29. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses]. Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589 [TBL] [Abstract][Full Text] [Related]
30. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804 [TBL] [Abstract][Full Text] [Related]
31. Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. Durot E; Michallet AS; Leprêtre S; Le QH; Leblond V; Delmer A Eur J Haematol; 2015 Aug; 95(2):160-7. PubMed ID: 25359318 [TBL] [Abstract][Full Text] [Related]
32. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141 [TBL] [Abstract][Full Text] [Related]
33. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia. Liliemark JO; Gahrton G; Paul CY; Peterson CO Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691 [TBL] [Abstract][Full Text] [Related]